The role of ixazomib as an augmented conditioning therapy in salvage autologous stem cell transplant (ASCT) and as a post-ASCT consolidation and maintenance strategy in patients with relapsed multiple myeloma (ACCoRd [UK-MRA Myeloma XII] trial): study protocol for a Phase III randomised controlled trial

Striha, A orcid.org/0000-0003-3363-8417, Ashcroft, AJ, Hockaday, A et al. (12 more authors) (2018) The role of ixazomib as an augmented conditioning therapy in salvage autologous stem cell transplant (ASCT) and as a post-ASCT consolidation and maintenance strategy in patients with relapsed multiple myeloma (ACCoRd [UK-MRA Myeloma XII] trial): study protocol for a Phase III randomised controlled trial. Trials, 19. 169. p. 169. ISSN 1745-6215

Abstract

Metadata

Authors/Creators:
Copyright, Publisher and Additional Information: © The Author(s). 2018 Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
Keywords: ASCT; Multiple Myeloma; Augmented ASCT; Randomised; Depth of response; Haematology
Dates:
  • Published: 7 March 2018
  • Accepted: 18 January 2018
  • Published (online): 7 March 2018
Institution: The University of Leeds
Academic Units: The University of Leeds > Faculty of Medicine and Health (Leeds) > School of Medicine (Leeds) > Inst of Clinical Trials Research (LICTR) (Leeds)
Funding Information:
FunderGrant number
Millennium Pharmaceuticals Inc.X16045
Depositing User: Symplectic Publications
Date Deposited: 13 Mar 2018 14:58
Last Modified: 01 Mar 2019 16:18
Status: Published
Publisher: BioMed Central
Identification Number: https://doi.org/10.1186/s13063-018-2524-8

Share / Export

Statistics